BioSpace News Archive

The Industry-Leading Engagement and Digital Communication Solutions from EnlivenHealth Aim to Achieve Lifelong Optimal Health for Patient Populations MOUNTAIN VIEW, Calif.--( BUSINESS WIRE )-- Omnicell, Inc., (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that it is launching EnlivenHealth™, a division dedicated to enabling retail pharmacies and health plans t

Revance to Present Three New Abstracts Evaluating DaxibotulinumtoxinA for Injection and Two ePosters Evaluating the RHA® Collection During the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting - Two oral presentations highlighting new data on DaxibotulinumtoxinA for Injection from the SAKURA Phase 3 program, the largest aesthetic neuromodulator clinical program ever conducted for the treatment of glabellar (frown) lines – - One

Independent Data Monitoring Committee recommended on September 30, 2020 that the study continue into Phase 3 based on a positive evaluation of safety and tolerability data from the Phase 2 lead-in Initial Phase 3 results may be available as early as the end of 2020; results for the primary endpoint are expected in the first quarter of 2021, with current estimates at January 2021 If successful, VIR-7831 has the potential to advance outpatient treatment for COVID-19 Patient enrollment underway;

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it will be presenting at the Alliance for Regenerative Medicine’s (ARM) virtual Cell and Gene Meeting on the Mesa , taking place October 12-16, 2020. Michael Redman, Executive Vice President and Chief Operating Offi

FDA clearance received to proceed with investigator- led multi-center double blind randomized clinical study in the U . S . with nomacopan following prior expanded access program Following initial proof of principle study in Brazil and subsequent Data and Safety Monitoring Board (DSMB) review, a double blind randomized clinical study with nomacopan is recruiting patients in Brazil Akari to present an update of its COVID-19 pneumonia pro

Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced the appointment of Franz B. Humer, Ph.D., as Executive Chairman of the Board of Directors. A world-renowned pharmaceutical industry trailblazer, Dr. Humer ser

Mesuron Inc. is a US commercial company specializing in the development and fabrication of SQUID-based magnetometers for various applications

Kai Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, TX, will advance Empower COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses, colleges and universities

AIM ImmunoTech Inc. (NYSE American: AIM) is pleased to announce that it has received Institutional Review Board (IRB) approval for the expansion of the AMP-511 Expanded Access Program (EAP) clinical trial for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) to include patients previously diagnosed with SARS-CoV-2, but who still demonstrate chronic fatigue-like symptoms

RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the publication by Dr. David Fuller and his colleagues of a review article entitled “Ampakines Stimulate Phrenic Motor Output after Cervical Spinal Cord Injury” in a special issue of the peer-reviewed journal,